Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07304934

A Single-arm, Prospective, Multi-center Cohort Study Based on Deep Learning-based cfDNA Fragment Omics to Verify the TuFEst Model for the Staging Diagnosis of Breast Cancer Lesions and Lymph Nodes

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
269 (estimated)
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
Sex
Female
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Through the research of this project, we expect to achieve the cfDNA fragment omics liquid biopsy technology based on deep learning, verify the accuracy of the TuFEst model in predicting the tumor burden status of breast cancer lesions and lymph nodes in newly diagnosed breast cancer patients and those receiving neoadjuvant therapy, and provide a theoretical basis for large-scale clinical application in the future

Detailed description

1. Based on the previously established TuFEst model, the cfDNA fragment omics liquid biopsy technology based on deep learning is utilized to predict the tumor burden status of breast cancer lesions and lymph nodes, thereby enhancing the accuracy of early diagnosis of breast cancer: This study will collect and analyze blood samples from breast cancer patients at different stages, and use deep learning-based cfDNA fragment omics liquid biopsy technology to extract tumor-related cfDNA fragments and construct a cfDNA fragment omics feature library. Predictions are made based on the TuFEst model. Then, accuracy matching and evaluation are carried out according to the prediction results and the actual breast cancer lesion and lymph node tumor burden status. Verify the efficacy of the TuFEst model in the staging diagnosis of breast cancer. 2. To evaluate the sensitivity, specificity, accuracy and repeatability of the TuFEst model to determine its reliability in clinical application: This study will collect a larger number of blood samples from breast cancer patients based on the previous retrospective cohort to assess the performance of the model in a larger sample prospective cohort. This study will also explore the application of this technology in the monitoring of neoadjuvant therapy for breast cancer, specifically evaluating its application in post-treatment staging diagnosis of breast cancer, prediction of treatment effects, and monitoring of tumor recurrence.

Conditions

Interventions

TypeNameDescription
OTHERNo Intervention: Observational CohortNo Intervention: Observational Cohort

Timeline

Start date
2025-12-01
Primary completion
2027-12-31
Completion
2027-12-31
First posted
2025-12-26
Last updated
2025-12-26

Source: ClinicalTrials.gov record NCT07304934. Inclusion in this directory is not an endorsement.